Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
ASJC Scopus subject areas
- Cancer Research
Gautschi, O., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P. C., Gumerlock, P. H., Kung, H. J., Stahel, R. A., Gandara, D. R., & Betticher, D. C. (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Letters, 254(2), 265-273. https://doi.org/10.1016/j.canlet.2007.03.008